Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Noted Food Safety Expert Michael R. Taylor Named Advisor To FDA Commissioner
Michael R. Taylor, J.D., a nationally recognized food safety expert and research professor at George Washington University"s School of Public Health and Health Services, will return to the U.S. Food and Drug Administration to serve as senior advisor to the commissioner.
generic viagra online
What Is Cerebral Palsy? What Causes Cerebral Palsy?
Cerebral palsy is a term which encompasses a set of neurological conditions that cause physical disability in human development - they affect the brain and nervous system. The word cerebral refers to the area in the brain that is affected, while palsy means complete or partial muscle paralysis, frequently accompanied by loss of sensation and uncontrollable body movements or tremors. Cerebral means related to the brain or cerebrum. Cerebrum is a Latin word meaning "brain; top of the head, skull". In the English language the cerebrum is the anterior (front) portion of the brain consisting of two hemispheres; it is the dominant part of the brain in humans.
News of the day
OSI Pharmaceuticals Announces Acceptance Of Tarceva Supplemental New Drug Application For Review By The U.S. Food And Drug Administration
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental New Drug Application (sNDA) for the use of Tarceva® (erlotinib) as a first-line maintenance treatment for patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following first-line treatment with platinum-based chemotherapy. Based upon the March 17th receipt of filing the FDA Prescription Drug Fee Act (PDUFA) review date will be on or about January 18, 2010.
Health Insurance

A Group Of Proteins Highly Effective At Killing Bacteria And Which Could Hold The Key To Developing New Types Of Antibiotics To Be Studied

Researchers from the Universities of York and Leeds have been awarded ÷£3.3m from the Biotechnology and Biological Sciences Research Council (BBSRC) to find out how a family of proteins known as colicins force their way into bacterial cells before destroying them. The team, led by Professor Colin Kleanthous, from the University of York"s Department of Biology, will develop earlier research that suggests colicins use decoys to mimic key parts of the cells" own protein machinery to evade their defences. Professor Kleanthous said: "Colicins are the weapon used in the biological warfare that takes place between competing bacteria. Understanding how this group of proteins work could help scientists develop new drug delivery methods to target the bacteria that cause diseases in people." "It"s as though the colicins are carrying the equivalent of hand grenades which they can deploy without harming themselves," said Professor Sheena Radford of the University of Leeds" Faculty of Biological Sciences. The five year programme of research aims to discover how colicins specifically penetrate Gram-negative bacteria which are protected by two membrane barriers. It will involve collaboration between six groups of scientists from the Departments of Biology and Chemistry at the University of York and the Astbury Centre for Structural and Molecular Biology, Faculty of Biological Sciences, at the University of Leeds. James Reed University of York


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009